Vital Signs
Landmark Study Focuses on Treatment of Alzheimer’s Disease in Black Americans
According to the Alzheimer’s Association, the brain-destroying illness Alzheimer’s disease is an emerging public health crisis among older African Americans. Not only is the incidence of Alzheimer’s much higher in black Americans than in whites, but black patients also tend to be diagnosed at a later stage of the disease, when cognitive function has already declined substantially. And the crisis is expected to grow as more black baby boomers age: The number of African Americans aged 65 and older will more than double by the year 2030.
Although there is no cure for Alzheimer’s disease, medical treatments such as the popular drug Aricept® (donepezil HCI tablets) can help ease some of the disease’s devastating symptoms. Now a landmark study--the first clinical trial to assess the benefit of Aricept treatment exclusively in African Americans--reports that black patients with mild to moderate Alzheimer’s experienced significant improvements in cognition and global function after being treated with the drug for a 12-week period. The study’s findings were presented in April at the 57th annual meeting of the American Academy of Neurology.
The Treatment of Alzheimer’s in African American Patients (TAAAP) clinical trial studied 126 African American patients from 26 locations across the U.S. After up to four weeks of screening and a one-week baseline period, they were given open-label Aricept, 5mg/day, which was increased to 10 mg after four weeks at the discretion of the investigator. Measurements were taken at baseline and at four-week intervals. After 12 weeks, most patients treated with the drug showed significantly improved scores on such cognitive tests as the Mini-Mental State Examination, the Clinician’s Interview-Based Impression of Change and the Fuld Object Memory Evaluation.
“These findings are important because they suggest the benefits of treatment with Aricept in African American patients with mild to moderate Alzheimer’s disease,” says the TAAAP study’s lead investigator, Patrick Griffith, MD, professor of clinical medicine at Morehouse School of Medicine in Atlanta. “This should serve as a call to action for African American patients, caregivers and their physicians to watch for early signs of Alzheimer’s disease symptoms, such as memory loss, and intervene with treatment.”
Similar Articles
- Want to Help Fight AIDS in the Black Community? Play Bid Whist!
- Advice for Increasing Minority Cancer Screening Rates: THINK POSITIVE!
- A New Weapon in the War Against Sickle-Cell Disease
- ISHIB Offers Guidelines for Treating Hypertension in African Americans
- Correlation Found Between Poor Nutrition and Disease for African Americans
Featured Content
EVENT
TITLE: Hispanic Nurses: Transforming Policy to Support Healthy Communities for Hispanics ORGANIZATION: 35th Annual National Association Of Hispanic Nurses ConferenceEMPLOYER
NAME: University of Washington Medical Center LOCATION: Seattle, WA DESCRIPTION:Located in Seattle, University of Washington Medical Center provides comprehensive primary care services and serves as a regional referral and treatment center for specialized medical care. Recognized as the first Magnet* hospital in the U.S., our commitment to nursing excellence has been honored for an unprecedented fourth consecutive time — the only hospital in the world to achieve this — and serves as a testament to our dedication to our staff.
READ MORE READ ALLJOB POSTING
POSITION: Nurse-Midwifery Tenure Track Faculty Member EMPLOYER: University of California, San Francisco, School of Nursing, Department of Family Health Care Nursing DESCRIPTION:Nurse-Midwifery Tenure Track Faculty Member
Assistant, Associate, or Full Professor Rank*
Education:
Minimum criteria:
1. Doctoral degree in nursing or related field.
2. Graduate level education and training in midwifery specialty.
3. Certification as a midwife from the American College of Nurse Midwives.
Highly desirable criteria:
READ MORE READ ALL